BRAF and melanoma: Our results suggest that combining clinically approved γ–secretase inhibitors, which block Notch activation, with BRAF inhibitors, which block BRAF-MEK-ERK signaling, might be a more effective treatment of BRAF/NRAS mutant melanomas.